A study looking at the use of multiparametric Magnetic Resonance Imaging (MRI) and Positron Emission Tomography - Computed Tomography (PET-CT) to evaluate radiological changes after lung stereotactic ablative radiotherapy (SABR).

Phase 2

Completed

• Conditions: on small cell lung cancer (NSCLC); Oligometastatic disease involving lung; Non small cell lung cancer (NSCLC); Cancer - Lung - Non small cell; Cancer - Other cancer types

• Registration Number: ACTRN12616000801415
• Lead Sponsor: iverpool Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-06-20
• Study Completion: 2023-09-10
• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

Patients undergoing SABR for Stage I/II NSCLC or lung oligometastases
Able to attend follow up for 2 years
Over 18 years of age

Exclusion Criteria

Prognosis less than 2 years
Patient refusal
Contraindication to MRI
Inability to give informed consent
Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To qualitatively assess post SABR tumour response which will be determined through radiological assessment (MRI scans with or without PET-CT) and physical examination. [ 6 monthly up to 24 months following radiotherapy treatment. ];To quantitatively assess post SABR tumour response which will be determined through radiological assessment (MRI scans with or without PET-CT) and physical examination. [ 6 monthly up to 24 months following radiotherapy treatment. ]